http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2262839-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b294cd24df4ded8b0da4548ba42756ba |
| publicationDate | 2012-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2262839-B1 |
| titleOfInvention | Use of an anti-cd151 antibody for early treatment of cancer |
| abstract | The invention relates to the use of at least one antibody, or one of its functional fragments, that can bind to the protein CD151, thereby inhibiting tumour growth, for preparing a medicament for the early treatment of cancer. The invention also relates to a composition for treating cancer, comprising at least one anti-CD151 antibody, or one of the functional fragments thereof, as an active principle, that can bind to the protein CD151 and/or inhibit its metastasis-promoting activity, said antibodies being the antibodies secreted by the hybridoma filed at the ATCC under the number CRL-2696. |
| priorityDate | 2008-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 464.